Metabolic & Cardiometabolic
stopping GLP-1 receptor agonists causes substantial weight regain
In plain terms: If I stop a GLP-1 drug, will I gain the weight back?
Part of: 💊 GLP-1 Drugs
Yes — trials and pooled data consistently show people regain about two-thirds of lost weight within ~1 year of stopping, so these drugs work like chronic therapy rather than a cure.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Wilding 2022 · Diabetes Obes Metab | RCT | supports | high | STEP-1 extension: after withdrawal, semaglutide group regained 11.6 of 17.3 percentage-pts lost by wk120 (~two-thirds); BP/lipids reverted too. |
| Wilding 2021 · N Engl J Med | RCT | supports | high | STEP-1 main trial establishes the ~14.9% on-drug loss that is largely reversed on withdrawal (baseline for extension regain). |
| Rubino 2021 · Ann Intern Med | RCT | supports | moderate | Synopsis of STEP-4: continued semaglutide maintained loss while withdrawal produced regain; corroborates primary. |
| Amorim 2026 · Chronic Dis Transl Med | observational | supports | low | Review flags durability/duration as key gap; benefits wane without continued GLP-1RA exposure. |
| Damen 2026 · Ann Intern Med | meta-analysis | supports | high | Living network MA for ACP notes weight benefits of obesity pharmacotherapy are not durable after discontinuation. |
| Berg 2025 · Obes Rev | meta-analysis | supports | high | SR/MA (n=2372): after stopping, regain proportional to loss — liraglutide +2.20kg, semaglutide/tirzepatide +9.69kg; regardless of lifestyle. |
| Aronne 2024 · JAMA | RCT | supports | high | SURMOUNT-4: stopping tirzepatide gave +14.0% vs -5.5% continued (difference 19.4 pts); only 16.6% of placebo kept >=80% loss. |
| Ritsinger 2026 · Diabetes Obes Metab | observational | mixed | moderate | Real-world context: sustained risk reduction presupposes sustained treatment/weight control, undermined by discontinuation. |
| McGowan 2025 · Nat Med | meta-analysis | supports | high | SR/MA of obesity pharmacotherapy: maximal weight loss is treatment-duration dependent; cessation reverses gains. |
| Kramer 2024 · J Clin Endocrinol Metab | observational | mixed | moderate | GLP-1RA after bariatric surgery: weight trajectory depends on continued treatment; supports chronic-therapy framing. |
| Rubino 2021 · JAMA | RCT | supports | high | STEP-4 withdrawal: switching to placebo at wk20 led to +6.9% regain vs -7.9% with continued semaglutide (difference ~14.8 pts). |
| Hamarsheh 2026 · Endocrinol Diabetes Metab | meta-analysis | mixed | moderate | NMA of anti-obesity drugs: efficacy is on-treatment; durability requires ongoing therapy, consistent with regain on stopping. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.